MiNK Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $5.8M | $6.3M | $15.5M | $23.1M | $14.0M | $9.5M |
| SG&A Expense | — | $6.7M | $4.3M | $7.4M | $7.8M | $4.6M | $1.3M |
| Operating Income | — | $-12.6M | $-11.3M | $-22.9M | $-30.9M | $-28.4M | $-14.6M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | $-110.0K | $-93.0K | $-28.0K | — | $2.4M | $2.4M |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — |
| Net Income | — | $-12.5M | $-10.8M | $-22.5M | $-28.0M | $-30.2M | $-16.2M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-2.93 | $-2.86 | $-6.54 | $-0.83 | $-1.16 | $-0.67 |
| EPS (Diluted) | — | $-2.93 | $-2.86 | $-6.54 | $-0.83 | $-1.16 | $-0.67 |
| Shares Outstanding (Basic) | 5.0M | 4.3M | 3.8M | 3.4M | 33.7M | 26.0M | — |
| Shares Outstanding (Diluted) | 5.0M | 4.3M | 3.8M | 3.4M | 33.7M | 26.0M | — |
| Dividends Per Share | — | — | — | — | — | — | — |